{"id":25169,"date":"2023-09-16T12:00:00","date_gmt":"2023-09-16T17:00:00","guid":{"rendered":"https:\/\/myeloma.ca\/?p=25169"},"modified":"2025-08-19T08:28:09","modified_gmt":"2025-08-19T13:28:09","slug":"resultats-concrets-dune-autogreffe-de-cellules-souches-chez-les-personnes-ayant-recemment-recu-le-diagnostic-dun-myelome-multiple-un-rapport-issu-de-la-base-de-donnees-du-canadian","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2023\/09\/16\/resultats-concrets-dune-autogreffe-de-cellules-souches-chez-les-personnes-ayant-recemment-recu-le-diagnostic-dun-myelome-multiple-un-rapport-issu-de-la-base-de-donnees-du-canadian\/","title":{"rendered":"R\u00e9sultats concrets d\u2019une autogreffe de cellules souches chez les personnes ayant r\u00e9cemment re\u00e7u le diagnostic d\u2019un my\u00e9lome multiple : un rapport issu de la base de donn\u00e9es du Canadian Myeloma"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">L\u2019autogreffe de cellules souches demeure une option importante pour les patients atteints d\u2019un my\u00e9lome multiple (MM) admissibles dans le cadre du traitement initial. En utilisant la base de donn\u00e9es nationale du Canadian Myeloma Research Group (CMRG), les d\u00e9tails et les r\u00e9sultats d\u2019une autogreffe de cellules souches ont \u00e9t\u00e9 examin\u00e9 dans le cadre du traitement de premi\u00e8re intention chez les patients canadiens atteints d\u2019un my\u00e9lome multiple admissibles entre 2007 et 2021.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Pour en savoir plus, <a href=\"https:\/\/www.nature.com\/articles\/s41408-023-00905-8\" target=\"_blank\" rel=\"noopener\" title=\"\">cliquez ici.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>L\u2019autogreffe de cellules souches demeure une option importante pour les patients atteints d\u2019un my\u00e9lome multiple (MM) admissibles dans le cadre du traitement initial. En utilisant la base de donn\u00e9es nationale du Canadian Myeloma Research Group (CMRG), les d\u00e9tails et les r\u00e9sultats d\u2019une autogreffe de cellules souches ont \u00e9t\u00e9 examin\u00e9 dans le cadre du traitement de [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[53,58],"tags":[],"class_list":["post-25169","post","type-post","status-publish","format-standard","hentry","category-actualites-et-evenement","category-nouvelles-de-myelome-canada"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/25169","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=25169"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/25169\/revisions"}],"predecessor-version":[{"id":25170,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/25169\/revisions\/25170"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=25169"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=25169"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=25169"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}